This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP for Lateral Epicondylitis.  

The Platelet Rich Plasma “PRP” Market is valued at 828.8 Billion in 2023, and is estimated to grow to over 3 Trillion by 2032. Lateral Epicondylitis is a common indication among adult men and women, ages 30 to 50. It is often treated with PRP. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Lateral Epicondylitis. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Lateral Epicondylitis cases, outcomes and other case data.